vs

Side-by-side financial comparison of Amneal Pharmaceuticals, Inc. (AMRX) and FLOWERS FOODS INC (FLO). Click either name above to swap in a different company.

FLOWERS FOODS INC is the larger business by last-quarter revenue ($1.2B vs $722.5M, roughly 1.7× Amneal Pharmaceuticals, Inc.). On growth, FLOWERS FOODS INC posted the faster year-over-year revenue change (11.0% vs 3.9%). Over the past eight quarters, Amneal Pharmaceuticals, Inc.'s revenue compounded faster (1.5% CAGR vs -11.6%).

Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.

Flowers Foods, headquartered in Thomasville, Georgia, is a producer and marketer of packaged bakery foods in the United States. The company operates 44 bakeries across 19 states that produce a variety of products, including bread, buns, rolls, snack cakes, pastries, and tortillas. As of February 2013, Flowers Foods had grown to be the "second-largest baking company in the United States."

AMRX vs FLO — Head-to-Head

Bigger by revenue
FLO
FLO
1.7× larger
FLO
$1.2B
$722.5M
AMRX
Growing faster (revenue YoY)
FLO
FLO
+7.1% gap
FLO
11.0%
3.9%
AMRX
Faster 2-yr revenue CAGR
AMRX
AMRX
Annualised
AMRX
1.5%
-11.6%
FLO

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AMRX
AMRX
FLO
FLO
Revenue
$722.5M
$1.2B
Net Profit
$78.0M
Gross Margin
44.3%
Operating Margin
19.6%
Net Margin
10.8%
Revenue YoY
3.9%
11.0%
Net Profit YoY
410.5%
EPS (diluted)
$0.19

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMRX
AMRX
FLO
FLO
Q1 26
$722.5M
Q4 25
$814.3M
$1.2B
Q3 25
$784.5M
$1.2B
Q2 25
$724.5M
$1.6B
Q1 25
$695.4M
Q4 24
$730.5M
$1.2B
Q3 24
$702.5M
$1.2B
Q2 24
$701.8M
$1.6B
Net Profit
AMRX
AMRX
FLO
FLO
Q1 26
$78.0M
Q4 25
$35.1M
$39.5M
Q3 25
$2.4M
$58.4M
Q2 25
$22.4M
$53.0M
Q1 25
$12.2M
Q4 24
$-31.1M
$65.0M
Q3 24
$-156.0K
$67.0M
Q2 24
$6.0M
$73.0M
Gross Margin
AMRX
AMRX
FLO
FLO
Q1 26
44.3%
Q4 25
36.5%
Q3 25
34.9%
Q2 25
39.5%
Q1 25
36.8%
Q4 24
36.0%
Q3 24
38.4%
Q2 24
35.6%
Operating Margin
AMRX
AMRX
FLO
FLO
Q1 26
19.6%
Q4 25
13.8%
5.4%
Q3 25
9.0%
7.5%
Q2 25
15.4%
5.5%
Q1 25
14.4%
Q4 24
10.4%
7.6%
Q3 24
12.6%
7.8%
Q2 24
13.6%
6.4%
Net Margin
AMRX
AMRX
FLO
FLO
Q1 26
10.8%
Q4 25
4.3%
3.2%
Q3 25
0.3%
4.7%
Q2 25
3.1%
3.4%
Q1 25
1.8%
Q4 24
-4.3%
5.5%
Q3 24
-0.0%
5.5%
Q2 24
0.9%
4.6%
EPS (diluted)
AMRX
AMRX
FLO
FLO
Q1 26
$0.19
Q4 25
$0.10
$0.19
Q3 25
$0.01
$0.28
Q2 25
$0.07
$0.25
Q1 25
$0.04
Q4 24
$-0.10
$0.31
Q3 24
$0.00
$0.32
Q2 24
$0.02
$0.34

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMRX
AMRX
FLO
FLO
Cash + ST InvestmentsLiquidity on hand
$197.7M
$12.1M
Total DebtLower is stronger
Stockholders' EquityBook value
Total Assets
$3.5B
$4.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMRX
AMRX
FLO
FLO
Q1 26
$197.7M
Q4 25
$282.0M
$16.7M
Q3 25
$201.2M
$11.0M
Q2 25
$71.5M
$7.3M
Q1 25
$59.2M
Q4 24
$110.6M
$15.0M
Q3 24
$74.0M
$6.9M
Q2 24
$43.8M
$15.8M
Total Debt
AMRX
AMRX
FLO
FLO
Q1 26
Q4 25
$2.6B
$1.8B
Q3 25
$2.6B
$1.7B
Q2 25
$2.2B
$1.8B
Q1 25
$2.2B
Q4 24
$2.4B
$1.1B
Q3 24
$2.4B
$1.1B
Q2 24
$2.4B
$1.0B
Stockholders' Equity
AMRX
AMRX
FLO
FLO
Q1 26
Q4 25
$-70.8M
$1.4B
Q3 25
$-109.5M
$1.4B
Q2 25
$-112.1M
$1.4B
Q1 25
$-131.7M
Q4 24
$-109.3M
$1.4B
Q3 24
$-93.4M
$1.4B
Q2 24
$-57.5M
$1.4B
Total Assets
AMRX
AMRX
FLO
FLO
Q1 26
$3.5B
Q4 25
$3.7B
$4.3B
Q3 25
$3.6B
$4.3B
Q2 25
$3.4B
$4.3B
Q1 25
$3.4B
Q4 24
$3.5B
$3.4B
Q3 24
$3.5B
$3.4B
Q2 24
$3.5B
$3.4B
Debt / Equity
AMRX
AMRX
FLO
FLO
Q1 26
Q4 25
1.25×
Q3 25
1.23×
Q2 25
1.26×
Q1 25
Q4 24
0.75×
Q3 24
0.77×
Q2 24
0.76×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMRX
AMRX
FLO
FLO
Operating Cash FlowLast quarter
$125.4M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMRX
AMRX
FLO
FLO
Q1 26
Q4 25
$130.3M
$54.4M
Q3 25
$118.5M
$130.8M
Q2 25
$83.8M
$135.6M
Q1 25
$7.4M
Q4 24
$118.1M
$113.9M
Q3 24
$141.8M
$63.3M
Q2 24
$39.7M
$105.1M
Free Cash Flow
AMRX
AMRX
FLO
FLO
Q1 26
Q4 25
$108.5M
$30.4M
Q3 25
$106.2M
$100.0M
Q2 25
$61.0M
$110.1M
Q1 25
$-5.8M
Q4 24
$102.9M
$88.6M
Q3 24
$124.8M
$35.4M
Q2 24
$29.0M
$71.8M
FCF Margin
AMRX
AMRX
FLO
FLO
Q1 26
Q4 25
13.3%
2.5%
Q3 25
13.5%
8.0%
Q2 25
8.4%
7.1%
Q1 25
-0.8%
Q4 24
14.1%
7.4%
Q3 24
17.8%
2.9%
Q2 24
4.1%
4.6%
Capex Intensity
AMRX
AMRX
FLO
FLO
Q1 26
Q4 25
2.7%
2.0%
Q3 25
1.6%
2.5%
Q2 25
3.2%
1.6%
Q1 25
1.9%
Q4 24
2.1%
2.1%
Q3 24
2.4%
2.3%
Q2 24
1.5%
2.1%
Cash Conversion
AMRX
AMRX
FLO
FLO
Q1 26
Q4 25
3.72×
1.38×
Q3 25
50.00×
2.24×
Q2 25
3.74×
2.56×
Q1 25
0.61×
Q4 24
1.75×
Q3 24
0.94×
Q2 24
6.62×
1.44×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons